You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,399,025


✉ Email this page to a colleague

« Back to Dashboard


Title:Modified release dosage forms of skeletal muscle relaxants
Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration--time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s): Venkatesh; Gopi M. (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee: ADARE PHARMACEUTICALS, INC. (Lawrenceville, NJ)
Filing Date:Dec 08, 2014
Application Number:14/563,580
Claims:1. A dosage form comprising a plurality of active-containing particles comprising cyclobenzaprine hydrochloride and a dissolution rate controlling polymer granulated together, wherein the dissolution rate controlling polymer is selected from the group consisting of ethers of cellulose and esters of cellulose; wherein the dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddles @ 50 rpm) in 900 mL of 0.1N HCl at 37.degree. C. exhibits a drug release profile substantially corresponding to the following pattern: after 2 hours, no more than about 40% of the total active is released; after 4 hours, from about 40-65% of the total active is released; and after 8 hours, from about 60-85% of the total active is released; and wherein the dosage form provides a therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions.

2. The dosage form of claim 1, wherein the particles are selected from the group consisting of pellets, beads, granules, and mini-tablets.

3. The dosage form of claim 1, wherein the particles are pellets.

4. The dosage form of claim 1, wherein the particles are beads.

5. The dosage form of claim 1, wherein the particles are granules.

6. The dosage form of claim 1, wherein the particles are mini-tablets.

7. The dosage form of claim 1, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride following oral administration of a single 30 mg cyclobenzaprine dose.

8. The dosage form of claim 1, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL following oral administration of a single 30 mg cyclobenzaprine dose.

9. The dosage form of claim 1, wherein said pharmaceutical dosage form provides a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

10. The dosage form of claim 1, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride, an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL, and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

11. The dosage form of claim 6, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine HCl, an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL, and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

12. A capsule filled with the dosage form of claim 1.

13. A capsule filled with the dosage form of claim 6.

14. The dosage form of claim 1, comprising 15 or 30 mg of cyclobenzaprine hydrochloride.

15. The dosage form of claim 6, comprising 15 or 30 mg of cyclobenzaprine hydrochloride.

16. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 1 to the patient.

17. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 6 to the patient.

18. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 10 to said patient.

19. A dosage form comprising a plurality of active-containing particles comprising cyclobenzaprine hydrochloride and a dissolution rate controlling polymer, granulated together; wherein the dissolution rate controlling polymer is selected from the group consisting of ethers of cellulose and esters of cellulose; wherein said dosage form comprises 30 mg of cyclobenzaprine hydrochloride and provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride following oral administration of a single 30 mg cyclobenzaprine dose; and wherein said dosage form provides a therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions.

20. The dosage form of claim 19, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL following oral administration of a single 30 mg cyclobenzaprine dose.

21. The dosage form of claim 20, wherein said pharmaceutical dosage form provides a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

22. The dosage form of claim 19, wherein the particles are selected from the group consisting of pellets, beads, granules, or mini-tablets.

23. The dosage form of claim 19, wherein the particles are pellets.

24. The dosage form of claim 19, wherein the particles are beads.

25. The dosage form of claim 19, wherein the particles are granules.

26. The dosage form of claim 19, wherein the particles are mini-tablets.

27. A capsule filled with the dosage form of claim 19.

28. A capsule filled with the dosage form of claim 26.

29. The dosage form of claim 26, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

30. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 19 to the patient.

31. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 26 to the patient.

32. A dosage form comprising a plurality of active-containing particles comprising cyclobenzaprine hydrochloride and a dissolution rate controlling polymer surrounding the cyclobenzaprine hydrochloride, wherein the dissolution rate controlling polymer is selected from the group consisting of ethers of cellulose and esters of cellulose; wherein the dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddles @ 50 rpm) in 900 mL of 0.1N HCl at 37.degree. C. exhibits a drug release profile substantially corresponding to the following pattern: after 2 hours, no more than about 40% of the total active is released; after 4 hours, from about 40-65% of the total active is released; and after 8 hours, from about 60-85% of the total active is released; and wherein the dosage form provides a therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions.

33. The dosage form of claim 32, wherein the particles are selected from the group consisting of pellets, beads, granules, and mini-tablets.

34. The dosage form of claim 32, wherein the particles are pellets.

35. The dosage form of claim 32, wherein the particles are beads.

36. The dosage form of claim 32, wherein the particles are granules.

37. The dosage form of claim 32, wherein the particles are mini-tablets.

38. The dosage form of claim 32, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride following oral administration of a single 30 mg cyclobenzaprine dose.

39. The dosage form of claim 32, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL following oral administration of a single 30 mg cyclobenzaprine dose.

40. The dosage form of claim 32, wherein said pharmaceutical dosage form provides a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

41. The dosage form of claim 32, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride, an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL, and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

42. The dosage form of claim 37, wherein the pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine HCl, an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL, and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

43. A capsule filled with the dosage form of claim 32.

44. A capsule filled with the dosage form of claim 37.

45. The dosage form of claim 32, comprising 15 or 30 mg of cyclobenzaprine hydrochloride.

46. The dosage form of claim 37, comprising 15 or 30 mg of cyclobenzaprine hydrochloride.

47. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 32 to the patient.

48. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 37 to the patient.

49. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 41 to said patient.

50. A dosage form comprising a plurality of active-containing particles comprising cyclobenzaprine hydrochloride and a dissolution rate controlling polymer surrounding the cyclobenzaprine hydrochloride; wherein the dissolution rate controlling polymer is selected from the group consisting of ethers of cellulose and esters of cellulose; wherein said dosage form comprises 30 mg of cyclobenzaprine hydrochloride and provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine hydrochloride following oral administration of a single 30 mg cyclobenzaprine dose; and wherein said dosage form provides a therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions.

51. The dosage form of claim 50, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL following oral administration of a single 30 mg cyclobenzaprine dose.

52. The dosage form of claim 50, wherein said pharmaceutical dosage form provides a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

53. The dosage form of claim 50, wherein the particles are selected from the group consisting of pellets, beads, granules, or mini-tablets.

54. The dosage form of claim 50, wherein the particles are pellets.

55. The dosage form of claim 50, wherein the particles are beads.

56. The dosage form of claim 50, wherein the particles are granules.

57. The dosage form of claim 50, wherein the particles are mini-tablets.

58. A capsule filled with the dosage form of claim 50.

59. A capsule filled with the dosage form of claim 57.

60. The dosage form of claim 57, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose.

61. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 50 to the patient.

62. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 57 to the patient.

63. A dosage form comprising a plurality of active-containing particles comprising cyclobenzaprine hydrochloride and a dissolution rate controlling polymer, granulated together; wherein the dissolution rate controlling polymer is selected from the group consisting of ethers of cellulose and esters of cellulose; wherein said dosage form comprises 30 mg of cyclobenzaprine hydrochloride and provides a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzaprine dose; and wherein said dosage form provides a therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions.

64. The dosage form of claim 63, wherein the pharmaceutical dosage form provides an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL following oral administration of a single 30 mg cyclobenzaprine dose.

65. The dosage form of claim 63, wherein the particles are selected from the group consisting of pellets, beads, granules, or mini-tablets.

66. The dosage form of claim 63, wherein the particles are pellets.

67. The dosage form of claim 63, wherein the particles are beads.

68. The dosage form of claim 63, wherein the particles are granules.

69. The dosage form of claim 63, wherein the particles are mini-tablets.

70. A capsule filled with the dosage form of claim 63.

71. A capsule filled with the dosage form of claim 69.

72. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 63 to the patient.

73. A method of relieving muscle spasms in a patient in need thereof, comprising orally administering the dosage form of claim 69 to the patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.